Joseph Shulman - Feb 9, 2022 Form 4 Insider Report for RHYTHM PHARMACEUTICALS, INC. (RYTM)

Role: Chief Technical Officer
Signature: /s/ Hunter Smith, Attorney-in-Fact for Joseph Shulman
Stock symbol: RYTM
Transactions as of: Feb 9, 2022
Transactions value $: $0
Form type: 4
Date filed: 2/11/2022, 08:34 PM
Next filing: Feb 15, 2022
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	RYTM	Restricted Stock Units	Award	$0	+10.6K		$0.00	10.6K	Feb 9, 2022	Common Stock	10.6K		Direct	F1, F2
transaction	RYTM	Stock Option (Right to Buy)	Award	$0	+63.8K		$0.00	63.8K	Feb 9, 2022	Common Stock	63.8K	$6.80	Direct	F3

Showing 1 to 2 of 2 entries

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
F2	The restricted stock units vest as to 25% of the total shares on each of February 9, 2023, February 9, 2024, February 9, 2025 and February 9, 2026. The restricted stock units have no expiration date.
F3	The stock options were granted on February 9, 2022. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.